干预性Cochrane系统评价中试验的预注册与发表模式
该研究从干预性Cochrane系统评价中随机抽取50篇,形成回顾性队列,聚焦主要结局,收集纳入、正在进行和待分类试验的预注册与发表信息。结果显示423项纳入试验中109项(25.7%)预注册,预注册试验覆盖60.1%的参与者,预注册试验发表比例达98.2%。作者认为即便在现代Cochrane系统评价中,预注册率仍低且注册试验未发表情况明显,但按参与者比例衡量,报告偏倚风险有所降低。
要点
- 50篇Cochrane系统评价中423项纳入试验仅109项(25.7%)预注册
- 各系统评价预注册比例中位数16.0%(四分位距0%-79.6%)
- 预注册试验覆盖全部参与者的60.1%,发表比例为98.2%
核心结论
- Cochrane系统评价纳入研究中预注册率仍低,注册试验未发表比例明显。
- 预注册试验按参与者计算贡献比例更高,注册试验中仅小部分参与者的结果未发表。
- 即使考虑参与者而非试验数,现代严格系统评价中报告偏倚风险仍高。
研究设计与样本
- 从干预性Cochrane系统评价中随机抽取50篇,形成回顾性队列。
- 聚焦各系统评价的主要结局,利用系统评价、已发表试验信息和公开试验注册文件收集资料。
- 收集信息涵盖纳入试验、正在进行试验和待分类研究。
主要发现
- 50篇系统评价共423项纳入试验评估主要结局,其中109项(25.7%)预注册。
- 各系统评价纳入试验预注册比例差异大,中位数16.0%(四分位距0%-79.6%)。
- 预注册试验覆盖全部参与者的60.1%,提示较大研究更可能预注册。
- 预注册试验中已发表参与者比例为98.2%;各系统评价间预注册试验的发表比例差异也很大。
关键数值与推荐
- 50篇随机抽取的干预性Cochrane系统评价中,423项纳入试验评估主要结局。
- 109项(25.7%)纳入试验为预注册。
- 各系统评价预注册比例中位数16.0%(四分位距0%-79.6%)。
- 预注册试验覆盖60.1%的参与者。
- 预注册试验中已发表参与者占98.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 无法检出未注册且从未发表的试验,结果可能低估问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: It is widely recognized that selective reporting clinical trial results based on their outcomes, in the forms of publication bias, outcome reporting bias, or p-hacking, has detrimental effects on the scientific literature and on evidence synthesis. This can be recognized and perhaps ameliorated with comprehensive trial registration. However, previous investigations of clinical trial registration focused on study-level examinations rather than the number of trial participants, which is often more relevant to meta-analysis. Our objective was to investigate the risk of bias from selective reporting considering both trials but also the number of included participants. METHODS: We took a random sample of 50 Cochrane systematic reviews (SRs) of interventions which included randomized controlled trials, forming a retrospective cohort. Focusing on the primary outcome in the SR we used the review, published trial information, and public trial registration documents to collect information about the reviews themselves, as well as information about "included," "ongoing," and studies "awaiting classification". RESULTS: In all 50 selected reviews, there were 423 "included" trials which examined the primary outcome, of which 109 (25.7%) were preregistered. There was substantial variability in proportions of preregistration of included trials among reviews, with a median of 16.0% (interquartile range 0%-79.6%). Registered trials covered 60.1% of all participants, suggesting larger studies were more likely to be preregistered. The proportion of participants in registered trials which were published was high (98.2%), but the proportion of registered trials which were published also varied substantially between reviews. CONCLUSION: We found that in Cochrane reviews, there remains a low rate of preregistration among included studies and evidence for a substantial rate of trial nonreporting of registered trials. However, preregistered trials contributed proportionally more patients to reviews, and findings remain unpublished for only a small proportion of participants in registered trials. PLAIN LANGUAGE SUMMARY: Trials are an important form of evidence in scientific literature that are often combined into systematic reviews (SRs), which give an overview for the evidence in a specific topic. However, trials and therefore the reviews can be misleading when the authors change the outcomes that they report based on the results they find, which is called reporting bias. One way of minimizing reporting bias is to register the planned methods for the trial in advance, known as preregistration. It is known that the proportion of trials that is registered can be low, but when conducting SRs the results are affected more by the number of participants within trials than the number of trials, which has not been previously studied. We aimed to make an up-to-date estimate of the proportion of preregistered trials in Cochrane SRs but also find out the proportion of participants within registered trials in these reviews. To do this we took a random sample of 50 Cochrane SRs, which conduct careful searches for registered trials whether or not they are published, and examined the trials within these reviews that studied the outcome the review declared to be most important. We found that even in modern SRs, only 25% of trials were preregistered, and that this number was very variable in reviews of different clinical questions. However we found that 60% of the patients in the reviews were within the preregistered trials, indicating that preregistered trials are generally larger than unregistered trials. We also found that more than 90% of preregistered studies were published. However, a major problem with this approach is that we cannot detect trials that were started without registration and then never published, which means that our results may underestimate the problem. Overall, this indicates that the risk of reporting bias is somewhat lower when considering participants rather than trials, but the risk of reporting bias is still high even in modern, rigorous reviews in medical science.
引用
- Bramley P, Bird C, Badgett R, et al. Patterns of preregistration and publication of trials in Cochrane systematic reviews of interventions. J Clin Epidemiol. 2025. PMID: 40902861. doi:10.1016/j.jclinepi.2025.111958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。